Skip to content

Ketamine: all studies

Page 350 of 448: studies 3,491 to 3,500 of 4,475, newest first. Back to the ketamine overview

Research

mTOR activation is required for the antidepressant effects of mGluR2/3 blockade

The International Journal of Neuropsychopharmacology November 24, 2011 Jason M. Dwyer, Ashley E. Lepack, Ronald S. Duman 169 citations

Recent studies demonstrate that ketamine, a fast-acting antidepressant, rapidly activates the mammalian target of rapamycin (mTOR) and increases synaptogenesis in the prefrontal cortex. Because of the side-effect and abuse potential of ketamine we are investigating alternative agents that produce similar effects. Here, we demonstrate that a single dose of LY 341495, an mGluR₂/₃ antagonist,...

DOI: 10.1017/s1461145711001702 (opens in new tab) Full text (opens in new tab) Ketamine Pi3k/akt/mtor pathway Antidepressant Synaptogenesis +12

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Science August 19, 2010 Nanxin Li, Boyoung Lee, Rongjian Liu et al. 2,875 citations

The rapid antidepressant response after ketamine administration in treatment-resistant depressed patients suggests a possible new approach for treating mood disorders compared to the weeks or months required for standard medications. However, the mechanisms underlying this action of ketamine [a glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonist] have not been identified. We observed...

DOI: 10.1126/science.1190287 (opens in new tab) Full text (opens in new tab) Ketamine Antidepressant Prefrontal cortex Pi3k/akt/mtor pathway +7

Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder

The Journal of Clinical Psychiatry July 13, 2010 Nancy Diazgranados, Lobna Ibrahim, Nancy E. Brutsché et al. 563 citations

OBJECTIVE: Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an N-methyl-D-asparate antagonist, has been reported to have antidepressant effects within hours. We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major...

Near-Death States Reported in a Sample of 50 Misusers

Substance Use & Misuse March 1, 2010 Ornella Corazza, Fabrizio Schifano 43 citations

Increase in recreational ketamine use may be a cause for concern. We aimed here at assessing, in a sample of ketamine misusers, concordance between the typical near-death experience (NDE) features and the on-drug psychoactive effects the subjects experienced. In 2003-2005, a sample of previous ketamine misusers recollecting a ketamine-related NDE were recruited through snowballing and screened...

The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.

Pharmaceuticals January 6, 2010 Rodrigo Machado‐Vieira, Jacqueline Baumann, Cristina Wheeler-Castillo et al.

Currently available antidepressants used to treat major depressive disorder (MDD) unfortunately often take weeks to months to achieve their full effects, commonly resulting in considerable morbidity and increased risk for suicidal behavior. Our lack of understanding of the precise cellular underpinnings of this illness and of the mechanism of action of existing effective pharmacological...

Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to anN-Methyl-D-Aspartate Antagonist

The Journal of Clinical Psychiatry September 8, 2009 Rodrigo Machado‐Vieira, Peixiong Yuan, Nancy E. Brutsché et al. 154 citations

OBJECTIVE: A model has been proposed to explain the pathophysiology of mood disorders based on decreased neurotrophin levels during mood episodes; treatment with antidepressants and mood stabilizers is associated with clinical improvement. This study investigated whether changes in brain-derived neurotrophic factor (BDNF) levels are associated with the initial antidepressant effects of...

"Research chemicals": tryptamine and phenethylamine use among high-risk youth.

Substance Use & Misuse 2008 Bill Sanders, Stephen E Lankenau, Jennifer Jackson Bloom et al.

Tryptamines and phenethylamines are two broad categories of psychoactive substances with a long history of licit and illicit use. Profiles of users of recently emerging tryptamines and phenethylamines are nonexistent, however, since surveillance studies do not query the use of these substances. This manuscript describes the types, modes of administration, onset of use, and context of use of a...

5-Year Trends in Use of Hallucinogens and Other Adjunct Drugs among UK Dance Drug Users

European Addiction Research December 18, 2006 Jim Mccambridge, Adam Winstock, Neil Hunt et al. 113 citations

<i>Aims:</i> To describe and assess trends in the use of hallucinogens and other adjunct drugs over a 5-year period. <i>Design:</i> Repeated-measures cross-sectional survey. <i>Setting and Participants:</i> Annual magazine-based survey targeting people who use drugs in dance contexts. <i>Measurements:</i> Lifetime use prevalence (ever used); age of first use; current use prevalence (any use...

DOI: 10.1159/000095816 (opens in new tab) Psilocybin Ketamine Hallucinogen Psychological intervention +4

The effects of psychoactive drugs and neuroleptics on language in normal subjects and schizophrenic patients: a review

European Psychiatry December 1, 2000 F. Salomé, P Boyer, Michel Fayol 21 citations

The aim of this survey is to present an overview of research into psychopharmacology as regards the effects of different psychoactive drugs and neuroleptics (NL) on language in normal subjects and schizophrenic patients. Eighteen studies that have investigated the effects of different drugs (alcohol, amphetamines, secobarbital, L-dopa, psilocybin, ketamine, fenfluramine) and neuroleptics...

DOI: 10.1016/s0924-9338(00)00520-4 (opens in new tab) Ketamine Psilocybin Amphetamine Schizophrenia object-oriented programming +9

Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation.

October 1, 1999 R. Andrew Chambers, J. Douglas Bremner, Bita Moghaddam et al. 140 citations

Dissociative cognitive and perceptual alterations commonly occur at the time of traumatization and as an enduring feature of post-traumatic stress disorder (PTSD). After stress exposure, dissociative symptoms are a predictor of the development of PTSD. Recent preclinical data suggest that stress stimulates the cortico-limbic release of glutamate. The glutamate that is released during stress in...

DOI: 10.153/scnp00400274 (opens in new tab) Ketamine Nmda receptor Glutamate receptor Dissociative +3